NCT05201430RecruitingPhase 3
Neoadjuvant FOLFOXIRI Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer
Neoadjuvant FOLFOXIRI Chemotherapy Versus CapeOX Chemotherapy for Local Advanced Rectal Cancer: An Open Label Randomized Controlled Phase III Trial
Source: ClinicalTrials.gov · Last updated 4 Mar 2022 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This is a phase III randomized controlled trial comparing the efficacy and safety of FOLFOXIRI versus CapeOX as neoadjuvant regimen in treating patients with middle and upper locally advanced (MRI T3-4 or N+) rectal cancer. This study aims to optimize the neoadjuvant therapy for patients with anus-preserving resectable locally advanced rectal cancer, so as to improve the prognosis of them. It remains unclear about whether FOLFOXIRI or CapeOX neoadjuvant chemotherapy is more effective for locally advanced rectal cancer.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- First submitted
- 4 Dec 2021
- Start date
- 27 Aug 2021
- Primary completion date
- Jun 2024
- Lead sponsor
- Fudan University
- Diseases
- Colorectal cancer
- NCT number
- NCT05201430
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 300
- From 27 Aug 2021 to the primary completion date, Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Cardiopulmonary dysfunction or liver and kidney dysfunction, and unable to tolerate chemotherapy or surgery;
- Have vital organ failure or other severe diseases, including but not limited to coronary heart disease, cardiovascular diseases, or myocardial infarction within 12 months before being included; severe neurological or psychiatric historysevere infection; active disseminated intravascular coagulation; active hepatitis, severe coagulation disorder patients;
Other illness
- Known to be allergic to capecitabine, 5-Fu, oxaliplatin or irinotecan;
- History of other malignancy within the past 5 years except effectively treated skin basal cell carcinoma, skin squamous cell carcinoma, or any in situ cancer;
- Serious organic disease including but not limited to heart, kidney, brain, and lung.
Other
- End-stage cachexia patients;
- Metastatic carcinoma;
- Incomplete or complete intestinal obstruction;
- Pregnant or lactating women; or women who have fertility but have not taken at taken adequate contraceptive measures;
Who the study is looking for
- MRI evaluated of T3-4 or N+ rectal cancer;
- Pathologically diagnosed of rectal adenocarcinoma;
- 18 to 75 years old;
- Distance from lower margin of tumor to anus \<15 cm and suitable for anus-preserving resection;
- Tumor amenable to radical resection;
- Treatment-na?ve patients with no previous systemic chemotherapy, radiotherapy or local excision for treating rectal cancer;
- Laboratory requirements conducted within 7 days of starting study treatment: Neutrophil count ≥ 1.5×10\^9/L, Platelet count ≥ 100×10\^9 /L, Hemoglobin ≥ 80 g/L, Serum bilirubin ≤ 24umol/L, Alanine aminotransferase and aspartate aminotransferase ≤ 60 U/L, Serum creatinine ≤ 110 umol/L;
- Be capable to receive a surgery;
- No second tumor at present or in the past 5 years, except skin basal cell carcinoma, skin squamous cell carcinoma, or any in situ cancer;
- No previous systemic chemotherapy for treating colorectal cancer;
- Life expectancy of more than 3 months;
- No current pregnancy or breast-feeding, and subjects at childbearing age shall take method of contraception;
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 1;
- Be willing and able to understand the study and to provide written informed consent.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Colorectal Surgery Fudan University Shanghai Caner Center Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.